Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Endoxifen levels in Breast Cancer patients and testing for CYP2D6

SABCS 2008

10 - 14 Dec 2008

Published: 9 Jan 2009

Views: 18125

Rating:

Save

Dr John Hawse, Department of Biochemistry and Molecular Biology, Mayo Clinic College of Medicine

Patients receiving tamoxifen therapy who can produce high levels of endoxifen have better survival than those producing low levels - why is this? Test needed for patients with CYP2D6 gene prior to administering tamoxifen

Related Videos

SOFT study: Clinical relevance of genomic alterations in premenopausal HR+...

Prof Sherene Loi - Peter MacCallum Cancer Centre, Melbourne, Australia

SOFT study: Clinical relevance of genomic alterations in premenopausal HR+, HER2- early breast cancer ( Prof Sherene Loi - Peter MacCallum Cancer Centre, Melbourne, Australia )

Metastatic bone disease: Importance of bone-targeted agents

Dr Alastair Greystoke - Newcastle University, Newcastle, UK and Prof Robert...

Metastatic bone disease: Importance of bone-targeted agents ( Dr Alastair Greystoke - Newcastle University, Newcastle, UK and Prof Robert Coleman - The University of Sheffield, Sheffield, UK )

Stereotactic body radiation therapy (SBRT) followed by sorafenib in HCC...

Prof Laura Dawson - University of Toronto, Toronto, Canada

Stereotactic body radiation therapy (SBRT) followed by sorafenib in HCC improves OS ( Prof Laura Dawson - University of Toronto, Toronto, Canada )

Choosing Wisely in implementing prevention, screening and early detection...

Dr Gad Murenzi - Rwanda Military Hospital, Kigali, Rwanda

Choosing Wisely in implementing prevention, screening and early detection programs in Africa ( Dr Gad Murenzi - Rwanda Military Hospital, Kigali, Rwanda )

Overview of the management of HER2-low breast cancer patients

Prof Hope Rugo - University of California San Francisco, San Francisco, USA

Overview of the management of HER2-low breast cancer patients ( Prof Hope Rugo - University of California San Francisco, San Francisco, USA )

Updates on HER2-low breast cancer

Prof Sana Al Sukhun - University of Jordan, Amman, Jordan

Updates on HER2-low breast cancer ( Prof Sana Al Sukhun - University of Jordan, Amman, Jordan )

Novel antibody-drug conjugates (ADCs) technologies for management of mBC

Prof Hope Rugo - University of California San Francisco, San Francisco, USA

Novel antibody-drug conjugates (ADCs) technologies for management of mBC ( Prof Hope Rugo - University of California San Francisco, San Francisco, USA )

Survival outcomes in randomised controlled trials with first-line CDK4/6i in...

Prof Matti Aapro - Genolier Cancer Centre, Genolier, Switzerland

Survival outcomes in randomised controlled trials with first-line CDK4/6i in HR+/HER2-Ve breast cancer ( Prof Matti Aapro - Genolier Cancer Centre, Genolier, Switzerland )

Spindle cell lesions of the breast

Prof Cecily Quinn - St Vincent’s University Hospital, Dublin, Ireland

Spindle cell lesions of the breast ( Prof Cecily Quinn - St Vincent’s University Hospital, Dublin, Ireland )

More from ecancer